+1 Recommend
0 collections
      • Record: found
      • Abstract: found
      • Article: not found

      Update on the use of dehydroepiandrosterone supplementation among women with diminished ovarian function.

      Journal of Assisted Reproduction and Genetics

      Adult, Case-Control Studies, Cohort Studies, Dehydroepiandrosterone, therapeutic use, Female, Humans, Infertility, Female, drug therapy, etiology, Menopause, Premature, drug effects, Ovary, physiology, Ovulation Induction, methods, Pregnancy, Pregnancy Rate, Premedication, trends, Primary Ovarian Insufficiency, complications, Retrospective Studies

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          We assessed the role of DHEA supplementation on pregnancy rates in women with diminished ovarian function. This is a case control study of 190 women with diminished ovarian function. The study group includes 89 patients who used supplementation with 75 mg daily of oral, micronized DHEA for up to 4 months prior to entry into in vitro fertilization (IVF). The control group is composed of 101 couples who received infertility treatment, but did not use DHEA. The primary outcome was clinical pregnancy after the patient's initial visit. We developed a Cox proportional hazards model to compare the proportional hazards of pregnancy among women using DHEA with the controls group. Cumulative clinical pregnancy rates were significantly higher in the study group (25 pregnancies; 28.4% vs. 11 pregnancies; 11.9%; relative hazard of pregnancy in study group (HR 3.8; 95% CI 1.2-11.8; p < 0.05). DHEA treatment resulted in significantly higher cumulative pregnancy rates. These data support a beneficial effect of DHEA supplementation among women with diminished ovarian function.

          Related collections

          Author and article information



          Comment on this article